Provided by Tiger Trade Technology Pte. Ltd.

Jade Biosciences

14.05
-0.1300-0.92%
Post-market: 14.050.00000.00%16:10 EDT
Volume:930.92K
Turnover:13.20M
Market Cap:893.54M
PE:-6.00
High:14.74
Open:14.43
Low:13.95
Close:14.18
52wk High:28.00
52wk Low:8.16
Shares:63.60M
Float Shares:47.12M
Volume Ratio:1.09
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3433
EPS(LYR):-3.1931
ROE:-89.18%
ROA:-33.59%
PB:0.31
PE(LYR):-4.40

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)

TIPRANKS
·
4 hours ago

Jade Biosciences: Pipeline Catalysts and JADE301 Potential Support Appealing Risk-Reward; Buy Rating Reiterated with Unchanged $42 Price Target

TIPRANKS
·
5 hours ago

Jade Biosciences advances JADE301 toward Phase 1 trial

TIPRANKS
·
Yesterday

Jade Biosciences announces preclinical data of JADE301

TIPRANKS
·
Yesterday

Jade Biosciences to Start Phase 1 Trial of Dermatomyositis Drug Candidate Jade301 in Q4 2026

Reuters
·
Yesterday

Jade Biosciences Announces Preclinical Data Characterizing Jade301, a Potentially Best-in-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody in Development for Dermatomyositis, at Eadv 2026

THOMSON REUTERS
·
Yesterday

Jade Biosciences, - Jade301 Shows About 25-Day Half-Life and Predictable Muscle Distribution in Primates

THOMSON REUTERS
·
Yesterday

Jade Biosciences, - Jade301 Demonstrates High-Affinity, Selective Ifn-Β Binding and Greater Potency than Dazukibart

THOMSON REUTERS
·
Yesterday

Jade Biosciences, - Phase 1 Trial for Jade301 to Begin in Q4 2026; Interim Data in H2 2027

THOMSON REUTERS
·
Yesterday

Jade Biosciences, - Jade301 Well Tolerated in Non-Human Primates at All Subcutaneous Doses

THOMSON REUTERS
·
Yesterday

Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says

MT Newswires Live
·
Sep 04

Jade Biosciences price target raised to $48 from $25 at Clear Street

TIPRANKS
·
Sep 04

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 04

Jade Biosciences to Present at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Jade Biosciences (JBIO) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage

Reuters
·
Aug 12

Jade Biosciences price target raised to $48 from $40 at Jefferies

TIPRANKS
·
Aug 12

Jade Biosciences is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 11

Jade Biosciences Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Analyst Julian Harrison Lifts Jade Biosciences Price Target to $77 and Reiterates Buy on Strong Pipeline and De-Risked IgA Program

TIPRANKS
·
Aug 11